Article
Immunology
Hweixian Leong Penny, Kelly Hainline, Nathaniel Theoharis, Bin Wu, Christian Brandl, Christian Webhofer, Mason McComb, Sabine Wittemer-Rump, Goekben Koca, Sabine Stienen, Ralf C. Bargou, Horst-Dieter Hummel, Wolfgang Loidl, Carsten Gruellich, Tobias Eggert, Ben Tran, Daniel T. Mytych
Summary: In oncology, the development of anti-drug antibodies (ADAs) has not been a major concern. However, with the increasing importance of T cell engagers in cancer immunotherapy, the impact of ADAs is becoming more significant. Understanding the formation of ADAs is crucial for the successful development of these biologics.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Oncology
Sarah B. Reusing, Dan A. Vallera, Angela R. Manser, Titus Vatrin, Sanil Bhatia, Martin Felices, Jeffrey S. Miller, Markus Uhrberg, Florian Babor
Summary: The text discusses the complexity and rarity of biphenotypic acute lymphoblastic leukemia in children, characterized by CD33 expression. Despite therapies targeting CD19, relapse and resistance remain challenges. Testing the BiKE on NK cells from healthy volunteers and leukemia patients showed enhanced effector functions against CD33(+) cells, suggesting potential as a therapeutic option.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2021)
Article
Oncology
Helene Bonnevaux, Stephane Guerif, Jana Albrecht, Erwan Jouannot, Thibaud De Gallier, Christian Beil, Christian Lange, Wulf Dirk Leuschner, Marion Schneider, Cendrine Lemoine, Anne Caron, Celine Amara, Cedric Barriere, Justine Siavellis, Valerie Bardet, Ernesto Luna, Pankaj Agrawal, Donald R. Drake, Ercole Rao, Peter Wonerow, Chantal Carrez, Veronique Blanc, Karl Hsu, Dmitri Wiederschain, Paula G. Fraenkel, Angela Virone-Oddos
Summary: CD123-CODV-TCE, a bispecific antibody, shows promising preclinical activity against AML by effectively targeting CD123 on malignant cells and inducing T-cell directed killing, suggesting it as a potential therapy for patients with relapsed/refractory AML.
Article
Medicine, Research & Experimental
Yu Lu, Ying Liu, Shupeng Wen, Na Kuang, Xuejun Zhang, Jianqiang Li, Fuxu Wang
Summary: CD7 CAR-T cells represent an effective treatment strategy for relapsed and refractory acute myeloid leukaemia patients, showing high cytotoxicity and the ability to inhibit leukemia cell growth.
JOURNAL OF TRANSLATIONAL MEDICINE
(2022)
Article
Oncology
Fatih M. Uckun, Justin Watts, Alice S. Mims, Prapti Patel, Eunice Wang, Paul J. Shami, Elizabeth Cull, Cynthia Lee, Christopher R. Cogle, Tara L. Lin
Summary: The study evaluated the risk, characteristics, and biomarkers of cytokine release syndrome (CRS) in patients receiving APVO436 for relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome. CRS incidence was not influenced by dose level, gender, race, obesity, or hematologic parameters, but age may play a role in CRS development.
Article
Biochemistry & Molecular Biology
Ke-xin Li, Hui-yang Wu, Wan-ying Pan, Meng-qi Guo, De-zhi Qiu, Yan-jie He, Yu-hua Li, Dong-Hua Yang, Yu-xian Huang
Summary: In this study, dual-target FLT3scFv/NKG2D-CART cells were constructed and found to effectively lyse AML cells. The FLT3 inhibitor gilteritinib was also shown to synergistically enhance the therapeutic effect of these CAR-T cells by upregulating NF-kappa B2-dependent NKG2DL expression in AML cells.
Article
Oncology
Fatih M. Uckun, Tara L. Lin, Alice S. Mims, Prapti Patel, Cynthia Lee, Anoush Shahidzadeh, Paul J. Shami, Elizabeth Cull, Christopher R. Cogle, Justin Watts
Summary: This study evaluated a new therapy for AML patients who had failed standard treatment options. The therapy, APVO436, showed favorable safety and preliminary evidence of efficacy, indicating the need for further investigation into its clinical impact potential.
Article
Oncology
Justin Watts, Tara L. Lin, Alice Mims, Prapti Patel, Cynthia Lee, Anoush Shahidzadeh, Paul Shami, Elizabeth Cull, Christopher R. Cogle, Eunice Wang, Fatih M. Uckun
Summary: APVO436 is a recombinant bispecific antibody that could be used to treat hematologic malignancies, particularly relapsed or refractory AML/MDS patients. Preliminary clinical trial results showed promising tolerability and activity of APVO436 in these patients, with activation of T cells.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Kim Klein, H. Berna Beverloo, Martin Zimmermann, Susana C. Raimondi, Christine von Neuhoff, Valerie Haas, Romy van Weelderen, Jacqueline Cloos, Jonas Abrahamsson, Yves Bertrand, Michael Dworzak, Alcira Fynn, Brenda Gibson, Shau-Yin Ha, Christine J. Harrison, Henrik Hasle, Sarah Elitzur, Guy Leverger, Alexei Maschan, Bassem Razzouk, Dirk Reinhardt, Carmelo Rizzari, Pter Smisek, Ursula Creutzig, Gertjan J. L. Kaspers
Summary: Cytogenetic profiles and karyotypic changes at relapse play a significant role in predicting survival outcomes for children with relapsed AML, with certain abnormalities associated with better or worse prognosis. Early treatment response, time to relapse, and cytogenetic profile at relapse are important prognostic factors, outweighing karyotypic instability per se.
PEDIATRIC BLOOD & CANCER
(2022)
Article
Hematology
Silvia Park, Daehun Kwag, Tong Yoon Kim, Jong Hyuk Lee, Joon Yeop Lee, Gi June Min, Sung Soo Park, Seung-Ah Yahng, Young-Woo Jeon, Seung-Hwan Shin, Jae-Ho Yoon, Sung-Eun Lee, Byung Sik Cho, Ki-Seong Eom, Yoo-Jin Kim, Seok Lee, Chang-Ki Min, Seok-Goo Cho, Jong Wook Lee, Hee-Je Kim
Summary: In medically fit patients with relapsed/refractory acute myeloid leukemia (R/R AML), venetoclax combined with low intensity treatment provides a comparable anti-leukemic response and survival to intensive chemotherapy (IC), while also offering better disease control and acting as a bridge to stem cell transplantation (SCT).
THERAPEUTIC ADVANCES IN HEMATOLOGY
(2022)
Article
Oncology
Hiroshi Moritake, Shiro Tanaka, Takako Miyamura, Hideki Nakayama, Norio Shiba, Akira Shimada, Kiminori Terui, Yuki Yuza, Katsuyoshi Koh, Hiroaki Goto, Harumi Kakuda, Akiko Saito, Daisuke Hasegawa, Shotaro Iwamoto, Takashi Taga, Souichi Adachi, Daisuke Tomizawa
Summary: The prognosis of relapsed pediatric AML depends on the duration from diagnosis to relapse and achieving a second complete remission (CR2) prior to HCT. Treatment with ECM or FLAG-based regimens may improve outcomes, while genetic factors like FLT3-internal tandem duplication can serve as poor prognostic markers.
PEDIATRIC BLOOD & CANCER
(2021)
Article
Oncology
Pierre-Yves Dumas, Emmanuel Raffoux, Emilie Berard, Sarah Bertoli, Marie-Anne Hospital, Mael Heiblig, Yohann Desbrosses, Caroline Bonmati, Cecile Pautas, Juliette Lambert, Corentin Orvain, Anne Banos, Florence Pasquier, Pierre Peterlin, Tony Marchand, Madalina Uzunov, Jamile Frayfer, Pascal Turlure, Thomas Cluzeau, Eric Jourdan, Chantal Himberlin, Emmanuelle Tavernier, Alban Villate, Stephanie Haiat, Marie-Lorraine Chretien, Martin Carre, Sylvain Chantepie, Ioana Vaida, Mathieu Wemeau, Safia Chebrek, Gaelle Guillerm, Romain Guieze, Houria Debarri, Eve Gehlkopf, Kamel Laribi, Ambroise Marcais, Alberto Santagostino, Marie-Christine Bene, Ariane Mineur, Arnaud Pigneux, Herve Dombret, Christian Recher
Summary: The real-world efficacy and safety of gilteritinib were assessed in a study of 167 R/R FLT3-mutated AML patients. The results showed that gilteritinib had a similar response rate and overall survival compared to the ADMIRAL trial, providing new insights into patients previously treated by intensive chemotherapy and midostaurin and beyond the 2nd line of treatment who can benefit from treatment in an outpatient setting.
Article
Hematology
Naohiro Sekiguchi, Senji Kasahara, Toshihiro Miyamoto, Toru Kiguchi, Hitoshi Ohno, Taiga Takagi, Masaya Tachibana, Hiroyuki Sumi, Yasuyuki Kakurai, Tomonari Yamashita, Kensuke Usuki
Summary: This is the first phase I study report of milademetan monotherapy in relapsed/refractory AML patients. The study results showed that oral milademetan is safe and well tolerated in R/R AML patients, but the trends in its safety and efficacy need further clinical investigation.
INTERNATIONAL JOURNAL OF HEMATOLOGY
(2023)
Article
Oncology
Anna Kopinska, Patryk Weglarz, Anna Koclega, Agata Wieczorkiewicz-Kabut, Krzysztof Wozniczka, Anna Armatys, Adrianna Spalek, Iwona Grygoruk-Wisniowska, Sebastian Grosicki, Aleksandra Butrym, Jaroslaw Czyz, Agata Obara, Tomasz Gromek, Grzegorz Helbig
Summary: This study analyzed the safety and efficacy of allogenic stem cell transplantation in patients with relapsed/refractory acute myeloid leukemia (r/r AML). The results showed that secondary AML and the number of pretransplantation treatment lines increased the risk of disease progression, while chronic graft versus host disease (cGVHD) had the opposite effect. The study emphasized the importance of early transplantation for r/r AML patients, even after unsatisfactory induction.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
(2023)
Article
Oncology
Evgenii Shumilov, Justin Hasenkamp, Markus Maulhardt, Paolo Mazzeo, Nicole Schmidt, Hristo Boyadzhiev, Wolfram Jung, Christina Ganster, Detlef Haase, Raphael Koch, Gerald Wulf
Summary: Second allogeneic stem cell transplantation is a rescue option for relapsed/refractory AML patients, but relapse rates remain high. Cell-based anti-relapse strategies can help achieve complete remission in some patients, despite poor cytogenetics. However, overall survival rates are still limited.
HEMATOLOGICAL ONCOLOGY
(2022)
